Continuously improving cancer-specific survival puts a growing proportion of cancer patients at risk of major adverse cardiovascular events (MACE), but tailored tools for cardiovascular risk prediction remain unavailable. Traditional cardiovascular risk factors and selected cancer types were linked to higher MACE risk. 

Read full article ( J Thromb Haemost. 2024 Nov;22(11):3125-3136) here: